Question 1

What is PDRadiopharma?

Accepted Answer

PDRadiopharma is a Entity.

Question 2

How often does PDRadiopharma appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was PDRadiopharma first tracked by Ergen?

Accepted Answer

First tracked on Jun 11, 2026.

Question 4

When was PDRadiopharma last mentioned in news?

Accepted Answer

Last active on Jun 11, 2026.

Question 5

What is PDRadiopharma's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is PDRadiopharma in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving PDRadiopharma?

Accepted Answer

Curium, PeptiDream complete prostate cancer trial (Jun 11, 2026, 6 articles).

Question 8

How did the "Curium, PeptiDream complete prostate cancer trial" event impact PDRadiopharma?

Accepted Answer

PDRadiopharma, a wholly-owned subsidiary of PeptiDream, is leading the regulatory filing, manufacturing, commercialization, and distribution of 64Cu-PSMA-I&T and 177Lu-PSMA-I&T in Japan. The completion of patient dosing in the Phase 2 trial is a significant step in its development of PSMA-targeted theranostics for prostate cancer patients in Japan.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.